About: COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
Creator	Wu, Bin Zhong, Jixin Zhou, Tao Rao, Xiaoquan Braunstein, Zachary Hou, Xiaoqiang Dong, Li Li, Huiling Zhong, Chen, Xiaoqi Chu, Aichun Dong, Lingli Huang, Anbin Huang, Qin Shen, Guifen Song, Shulin Su, Linchong Ye, Cong Ye, C Yang, Huiqin Zhang, Anbin Zhou, Wenyu Shen, G
source	Elsevier; Medline; PMC
abstract	BACKGROUND: In the ongoing COVID-19 pandemic, the susceptibility of patients with rheumatic diseases to COVID-19 remains unclear. We aimed to investigate susceptibility to COVID-19 in patients with autoimmune rheumatic diseases during the ongoing COVID-19 pandemic. METHODS: We did a multicentre retrospective study of patients with autoimmune rheumatic diseases in Hubei province, the epicentre of the COVID-19 outbreak in China. Patients with rheumatic diseases were contacted through an automated telephone-based survey to investigate their susceptibility to COVID-19. Data about COVID-19 exposure or diagnosis were collected. Families with a documented history of COVID-19 exposure, as defined by having at least one family member diagnosed with COVID-19, were followed up by medical professionals to obtain detailed information, including sex, age, smoking history, past medical history, use of medications, and information related to COVID-19. FINDINGS: Between March 20 and March 30, 2020, 6228 patients with autoimmune rheumatic diseases were included in the study. The overall rate of COVID-19 in patients with an autoimmune rheumatic disease in our study population was 0·43% (27 of 6228 patients). We identified 42 families in which COVID-19 was diagnosed between Dec 20, 2019, and March 20, 2020, in either patients with a rheumatic disease or in a family member residing at the same physical address during the outbreak. Within these 42 families, COVID-19 was diagnosed in 27 (63%) of 43 patients with a rheumatic disease and in 28 (34%) of 83 of their family members with no rheumatic disease (adjusted odds ratio [OR] 2·68 [95% CI 1·14–6·27]; p=0·023). Patients with rheumatic disease who were taking hydroxychloroquine had a lower risk of COVID-19 infection than patients taking other disease-modifying anti-rheumatic drugs (OR 0·09 [95% CI 0·01–0·94]; p=0·044). Additionally, the risk of COVID-19 was increased with age (adjusted OR 1·04 [95%CI 1·01–1·06]; p=0·0081). INTERPRETATION: Patients with autoimmune rheumatic disease might be more susceptible to COVID-19 infection than the general population. FUNDING: National Natural Science Foundation of China and the Tongji Hospital Clinical Research Flagship Program.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1016/s2665-9913(20)30227-7
bibo:pmid	32838309
has license	no-cc
sha1sum (hex)	f013ce72b775c4c402338ba633697e1d38135252
schema:url	https://doi.org/10.1016/s2665-9913%2820%2930227-7
resource representing a document's title	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study
has PubMed Central identifier	PMC7333992
has PubMed identifier	32838309
schema:publication	Lancet Rheumatol
resource representing a document's body	covid:f013ce72b775c4c402338ba633697e1d38135252#body_text
is schema:about of	named entity 'pandemic' named entity 'pandemic' named entity 'China' named entity 'COVID-19' named entity 'COVID-19 pandemic' named entity 'rheumatic disease' named entity 'China' named entity 'immunosuppressants' named entity 'China' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'rheumatic disease' named entity 'immunosuppression' named entity 'COVID' named entity 'clinical features' named entity 'antiinflammatory' named entity 'COVID-19' named entity 'student's t test' named entity 'autoimmune rheumatic diseases' named entity 'immunocompromised' named entity 'COVID' named entity 'Tongji Medical College' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'IL-1' named entity 'research articles' named entity 'COVID' named entity 'China' named entity 'COVID-19' named entity 'coronavirus infections' named entity 'RNA' named entity 'China' named entity 'viral infection' named entity 'corticosteroid therapy' named entity 'rheumatic diseases' named entity 'hydroxychloroquine' named entity 'severe acute respiratory syndrome' named entity 'infection' named entity 'rheumatic disease' named entity 'rheumatic disease' named entity 'RNA' named entity 'diabetes' named entity 'helper T cells' named entity 'infection' named entity 'COVID' named entity 'rheumatic disease' named entity 'hydroxychloroquine' named entity 'China' named entity 'COVID-19 outbreak' named entity 'SPSS' named entity 'ankylosing spondylitis' named entity 'infection' named entity 'automated telephone survey' named entity 'rheumatic diseases' named entity 'COVID-19' named entity 'rheumatic disease' named entity 'rheumatic condition'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software